Burning Rock Biotech Ltd
BNRNasdaq
$9.97
↑ +3.8%Jul 17 close · end-of-day
Price
1Y↑ +116.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$77.2M
Net Income (TTM)
-$7.9M
Free Cash Flow (TTM)
-$4.8M
Gross Margin
74.7%
Operating Margin
-10.2%
Net Margin
-10.3%
ROE
-10.3%
ROIC
-74.0%
Debt / Equity
0.0
Net Cash
$68.2M
Return 1Y
+116.3%
Company profile
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. Its products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer.
- CEO
- Yu S. Han
- Sector
- Services
- Industry
- Healthcare
- Employees
- 1,390
- Website
- brbiotech.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $65.9M | $79.7M | $81.7M | $75.7M | $70.7M | $77.2M |
| Gross profit | $48.1M | $57.1M | $55.1M | $51.2M | $49.6M | $57.6M |
| Operating income | -$63.2M | -$125.1M | -$142.1M | -$94.3M | -$49.0M | -$7.8M |
| Net income | -$62.4M | -$125.0M | -$140.8M | -$92.1M | -$47.5M | -$7.9M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$11.3M | -$75.0M | -$66.2M | -$36.0M | -$12.6M | -$4.1M |
| Free cash flow | -$20.5M | -$107.1M | -$75.2M | -$37.2M | -$13.4M | -$4.8M |
| Gross margin | 73.0% | 71.7% | 67.5% | 67.6% | 70.3% | 74.7% |
| Operating margin | -95.9% | -156.9% | -174.1% | -124.5% | -69.3% | -10.2% |
| Net margin | -94.7% | -156.9% | -172.4% | -121.6% | -67.2% | -10.3% |
No quarterly data.
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-26 | Han Yusheng | Buy | 24,900 | $8.00 | $199,090.44 | filing |
| 2026-06-24 | Han Yusheng | Buy | 250,000 | $8.00 | $2.0M | filing |
| 2026-06-23 | Han Yusheng | Buy | 5,990 | $7.50 | $44,920.21 | filing |
| 2026-06-22 | Han Yusheng | Buy | 104,650 | $7.45 | $779,673.90 | filing |
| 2026-06-16 | Han Yusheng | Buy | 111,110 | $9.00 | $999,956.67 | filing |
| 2026-06-12 | Han Yusheng | Buy | 210,000 | $9.25 | $1.9M | filing |
| 2026-06-11 | Han Yusheng | Buy | 24,760 | $8.74 | $216,387.54 | filing |
| 2026-03-31 | Han Yusheng | Buy | 314,870 | $17.36 | $5.5M | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.